



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent  
Licensee of the Blue Cross and Blue Shield Association

## Medical Policy

# Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias

### Table of Contents

- [Policy: Commercial](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [References](#)
- [Information Pertaining to All Policies](#)

### Policy Number: 190

BCBSA Reference Number: 8.01.22 (For Plan internal use only)

### Related Policies

- Hematopoietic Cell Transplantation for Autoimmune Diseases, #[192](#)
- Placental/Umbilical Cord Blood as a Source of Stem Cells, #[285](#)

### Policy

#### Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Allogeneic hematopoietic stem cell transplantation (HCT) is considered **MEDICALLY NECESSARY** for select patients with the following disorders:

#### Hemoglobinopathies

- Sickle cell anemia for children or young adults with either a history of prior stroke or at increased risk of stroke or end-organ damage
- Homozygous beta-thalassemia (i.e., thalassemia major).

#### Bone Marrow Failure Syndromes

- Aplastic anemia including hereditary (including Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond, Diamond-Blackfan) or acquired (e.g., secondary to drug or toxin exposure) forms.

#### Primary Immunodeficiencies\*

- Absent or defective T-cell function (e.g., severe combined immunodeficiency, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome)
- Absent or defective natural killer function (e.g. Chediak-Higashi syndrome)
- Absent or defective neutrophil function (e.g. Kostmann syndrome, chronic granulomatous disease, leukocyte adhesion defect).

\*The following lists the immunodeficiencies that have been successfully treated by allogeneic hematopoietic stem cell transplantation (allo-HCT) (Gennery & Cant et al, 2008).

### **Lymphocyte Immunodeficiencies**

- Adenosine deaminase deficiency
- Artemis deficiency
- Calcium channel deficiency
- CD 40 ligand deficiency
- Cernunnos/X-linked lymphoproliferative disease deficiency
- CHARGE syndrome with immune deficiency
- Common gamma chain deficiency
- Deficiencies in CD45, CD3, CD8
- DiGeorge syndrome
- DNA ligase IV deficiency syndrome
- Interleukin-7 receptor alpha deficiency
- Janus-associated kinase 3 (JAK3) deficiency
- Major histocompatibility class II deficiency
- Omenn syndrome
- Purine nucleoside phosphorylase deficiency
- Recombinase-activating gene (RAG) 1/2 deficiency
- Reticular dysgenesis
- Winged helix deficiency
- Wiskott-Aldrich syndrome
- X-linked lymphoproliferative disease
- Zeta-chain-associated protein-70 (ZAP-70) deficiency

### **Phagocytic Deficiencies**

- Chédiak-Higashi syndrome
- Chronic granulomatous disease
- Griscelli syndrome type 2
- Hemophagocytic lymphohistiocytosis
- Interferon-gamma receptor deficiencies
- Leukocyte adhesion deficiency
- Severe congenital neutropenias
- Shwachman-Diamond syndrome

### **Other Immunodeficiencies**

- Autoimmune lymphoproliferative syndrome
- Cartilage hair hypoplasia
- CD25 deficiency
- Hyper IgD and IgE syndromes
- ICF syndrome
- IPEX syndrome
- NEMO deficiency
- NF-κB inhibitor, alpha (IκB-alpha) deficiency
- Nijmegen breakage syndrome

### **Inherited Metabolic Diseases\*\***

- Lysosomal and peroxisomal storage disorders **except** Hunter, Sanfilippo, and Morquio syndromes

\*\*In the inherited metabolic disorders, allo-HCT has been proven effective in some cases of Hurler, Maroteaux-Lamy, and Sly syndromes, childhood onset cerebral X-linked adrenoleukodystrophy, globoid cell leukodystrophy, metachromatic leukodystrophy, alpha-mannosidosis, and aspartylglucosaminuria. Allogeneic HCT is possibly effective for fucosidosis, Gaucher types 1 and 3, Farber lipogranulomatosis, galactosialidosis, GM1 gangliosidosis, mucopolipidosis II (I-cell disease), multiple sulfatase deficiency, Niemann-Pick, neuronal ceroid lipofuscinosis, sialidosis, and Wolman disease. Allogeneic HSCT has not been effective in Hunter, Sanfilippo, or Morquio syndromes (Mehta, 2004).

### Genetic Disorders Affecting Skeletal Tissue

- Infantile malignant osteopetrosis (Albers-Schonberg disease or marble bone disease).

### Prior Authorization Information

#### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

#### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is <b>required</b> .
Commercial PPO and Indemnity	Prior authorization is <b>required</b> .

### Requesting Prior Authorization Using Authorization Manager

Providers will need to use [Authorization Manager](#) to submit initial authorization requests for services. Authorization Manager, available 24/7, is the quickest way to review authorization requirements, request authorizations, submit clinical documentation, check existing case status, and view/print the decision letter. For commercial members, the requests must meet medical policy guidelines.

To ensure the service request is processed accurately and quickly:

- Enter the facility's NPI or provider ID for where services are being performed.
- Enter the appropriate surgeon's NPI or provider ID as the servicing provider, *not* the billing group.

### Authorization Manager Resources

Refer to our [Authorization Manager](#) page for tips, guides, and video demonstrations.

### CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

*The following codes are included below for informational purposes only; this is not an all-inclusive list.*

The above **medical necessity criteria MUST** be met for the following codes to be covered for **Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

#### CPT Codes

CPT codes:	Code Description
38240	Bone marrow or blood-derived peripheral stem-cell transplantation; allogeneic

#### HCPCS Codes

HCPCS codes:	Code Description
S2142	Cord blood derived stem-cell transplantation, allogeneic

S2150	Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)
-------	---

## ICD-10 Procedure Codes

ICD-10-PCS procedure codes:	Code Description
30233G1	Transfusion of Nonautologous Bone Marrow into Peripheral Vein, Percutaneous Approach
30233X1	Transfusion of Nonautologous Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach
30233Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach
30243G1	Transfusion of Nonautologous Bone Marrow into Central Vein, Percutaneous Approach
30243X1	Transfusion of Nonautologous Cord Blood Stem Cells into Central Vein, Percutaneous Approach
30243Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach
30263G1	Transfusion of Nonautologous Bone Marrow into Central Artery, Percutaneous Approach
30263X1	Transfusion of Nonautologous Cord Blood Stem Cells into Central Artery, Percutaneous Approach
30263Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Central Artery, Percutaneous Approach
3E03305	Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach
3E04305	Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach
3E05305	Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach
3E06305	Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach

## Description

### Genetic Diseases and Acquired Anemias

#### Hemoglobinopathies

Thalassemias result from variants in the globin genes, resulting in reduced or absent hemoglobin production, thereby reducing oxygen delivery. The supportive treatment of  $\beta$ -thalassemia major requires life-long red blood cell transfusions that lead to progressive iron overload and the potential for organ damage and impaired cardiac, hepatic, and endocrine function. Sickle cell disease is caused by a single amino acid substitution in the beta chain of hemoglobin and, unlike thalassemia major, has a variable course of clinical severity.<sup>1</sup> Sickle cell disease typically manifests clinically with anemia, severe painful crises, acute chest syndrome, stroke, chronic pulmonary and renal dysfunction, growth retardation, neurologic deficits, and premature death. The mean age of death for patients with sickle cell disease has been demonstrated as 42 years for men and 48 for women.

#### Treatment

The only definitive cure for thalassemia is to correct the genetic defect with allogeneic hematopoietic cell transplantation (allo-HCT).

Three major therapeutic options are available for sickle cell disease: chronic blood transfusions, hydroxyurea, and allo-HCT, the latter being the only possibility for cure.<sup>1</sup>

### **Bone Marrow Failure Syndromes**

Aplastic anemia in children is rare; most often, it is idiopathic and, less commonly, due to a hereditary disorder. Inherited syndromes include Fanconi anemia, a rare, autosomal recessive disease characterized by genomic instability, with congenital abnormalities, chromosome breakage, cancer susceptibility, and progressive bone marrow failure leading to pancytopenia and severe aplastic anemia. Frequently, this disease terminates in myelodysplastic syndrome or acute myeloid leukemia. Most patients with Fanconi anemia succumb to the complications of severe aplastic anemia, leukemia, or solid tumors, with a median survival of 30 years of age.<sup>2</sup>

Dyskeratosis congenita is characterized by marked telomere dysregulation with clinical features of reticulated skin hyperpigmentation, nail dystrophy, and oral leukoplakia.<sup>3</sup> Early mortality is associated with bone marrow failure, infections, pulmonary complications, or malignancy.

Variants affecting ribosome assembly and function are associated with Shwachman-Diamond syndrome and Diamond-Blackfan syndrome.<sup>3</sup> Shwachman-Diamond has clinical features that include pancreatic exocrine insufficiency, skeletal abnormalities, and cytopenias, with some patients developing aplastic anemia. As with other bone marrow failure syndromes, patients are at increased risk of myelodysplastic syndrome and malignant transformation, especially acute myeloid leukemia. Diamond-Blackfan anemia is characterized by absent or decreased erythroid precursors in the bone marrow, with 30% of patients also having a variety of physical anomalies.<sup>3</sup>

#### **Treatment**

In Fanconi anemia, HCT is currently the only treatment that definitively restores normal hematopoiesis. Excellent results have been observed with the use of human leukocyte antigen (HLA)-matched sibling allo-HCT, with cure of the marrow failure and amelioration of the risk of leukemia.

### **Primary Immunodeficiencies**

The primary immunodeficiencies are a genetically heterogeneous group of diseases that affect distinct components of the immune system. More than 120 gene defects have been described, causing more than 150 disease phenotypes.<sup>4</sup> The most severe defects (collectively known as severe combined immunodeficiency) cause an absence or dysfunction of T lymphocytes and sometimes B lymphocytes and natural killer cells.<sup>4</sup>

#### **Treatment**

Without treatment, patients with severe combined immunodeficiency usually die by 12 to 18 months of age. With supportive care, including prophylactic medication, the lifespan of these patients can be prolonged, but long-term outlook is still poor, with many dying from infectious or inflammatory complications or malignancy by early adulthood.<sup>4</sup> Bone marrow transplantation is the only definitive cure, and the treatment of choice for severe combined immunodeficiency and other primary immunodeficiencies, including Wiskott-Aldrich syndrome and congenital defects of neutrophil function.<sup>5</sup>

### **Inherited Metabolic Diseases**

Lysosomal storage disorders consist of many different rare diseases caused by a single gene defect, and most are inherited as an autosomal recessive trait.<sup>6</sup> Lysosomal storage disorders are caused by specific enzyme deficiencies that result in defective lysosomal acid hydrolysis of endogenous macromolecules that subsequently accumulate as a toxic substance. Peroxisomal storage disorders arise due to a defect in a membrane transporter protein that leads to defects in the metabolism of long-chain fatty acids. Lysosomal storage disorders and peroxisomal storage disorders affect multiple organ systems, including the central and peripheral nervous systems. These disorders are progressive and often fatal in childhood due to both the accumulation of toxic substrate and a deficiency of the product of the enzyme reaction.<sup>6</sup> Hurler syndrome usually leads to premature death by 5 years of age.

#### **Treatment**

Exogenous enzyme replacement therapy is available for a limited number of the inherited metabolic diseases; however, these drugs do not cross the blood-brain barrier, which results in the ineffective treatment of the central nervous system. Stem cell transplantation provides a constant

source of enzyme replacement from the engrafted donor cells, which are not impeded by the blood-brain barrier.<sup>6</sup> The donor-derived cells can migrate and engraft in many organ systems, giving rise to different types of cells (eg, microglial cells in the brain and Kupffer cells in the liver).<sup>6</sup>

Allo-HCT has been primarily used to treat the inherited metabolic diseases that belong to the lysosomal and peroxisomal storage disorders, as listed in Table 1.<sup>6</sup> The first stem cell transplant for an inherited metabolic disease was performed in 1980 in a patient with Hurler syndrome. Since that time, more than 1000 transplants have been performed worldwide.<sup>6</sup>

Category	Diagnosis	Other Names
Mucopolysaccharidosis	Mucopolysaccharidosis I H or H/S Mucopolysaccharidosis II Mucopolysaccharidosis III A-D Mucopolysaccharidosis IV A-B Mucopolysaccharidosis VI Mucopolysaccharidosis VII	Hurler syndrome or Hurler-Scheie syndrome Hunter syndrome Sanfilippo syndrome A-D Morquio syndrome A-B Maroteaux-Lamy syndrome Sly syndrome
Sphingolipidosis	Fabry disease Farber disease Gaucher disease types 1 and 3 GM <sub>1</sub> gangliosidosis Niemann-Pick disease A and B Tay-Sachs disease Sandhoff disease Globoid cell leukodystrophy Metachromatic leukodystrophy	Lipogranulomatosis Krabbe disease MLD
Glycoproteinosis	Aspartylglucosaminuria Fucosidosis Alpha-mannosidosis Beta-mannosidosis Mucopolipidosis III and IV	Sialidosis
Other lipidoses	Niemann-Pick disease C Wolman disease Ceroid lipofuscinosis type III	Batten disease
Glycogen storage	Glycogen storage disease type II	Pompe disease
Multiple enzyme deficiency	Galactosialidosis Mucopolipidosis type II	I-cell disease
Lysosomal transport defects	Cystinosis Sialic acid storage disease Salla disease	
Peroxisomal storage disorders	Adrenoleukodystrophy Adrenomyeloneuropathy	ALD AMN

**Table 1. Lysosomal and Peroxisomal Storage Disorders**

### **Genetic Disorders Affecting Skeletal Tissue**

Osteopetrosis is a condition caused by defects in osteoclast development and/or function. The osteoclast (the cell that functions in the breakdown and resorption of bone tissue) is known to be part of the hematopoietic family and shares a common progenitor with the macrophage in the bone marrow.<sup>7</sup> Osteopetrosis is a heterogeneous group of heritable disorders, resulting in several different types of variable severity. The most severely affected patients are those with infantile malignant osteopetrosis (Albers-Schonberg disease or marble bone disease). Patients with infantile malignant osteopetrosis suffer from dense bone, including a heavy head with frontal bossing, exophthalmos, blindness by approximately 6 months of age, and severe hematologic malfunction with bone marrow failure.<sup>7</sup> Seventy percent of these patients die before the age of 6 years, often of recurrent infections.<sup>7</sup>

### **Treatment**

HCT is the only curative therapy for this fatal disease.

### **Hematopoietic Cell Transplantation**

HCT is a procedure in which hematopoietic stem cells are intravenously infused to restore bone marrow and immune function in cancer patients who receive bone marrow-toxic doses of cytotoxic drugs with or without whole-body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or a donor (allo-HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Cord blood transplantation is discussed in detail in policy #285.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. In allogeneic stem cell transplantation, immunologic compatibility between donor and patient is a critical factor for achieving a successful outcome. Compatibility is established by typing of HLA using cellular, serologic, or molecular techniques. HLA refers to the gene complex expressed at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. An acceptable donor will match the patient at all or most of the HLA loci.

### **Conditioning for Hematopoietic Cell Transplantation**

#### **Conventional Conditioning**

The conventional ("classical") practice of allo-HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to cause bone marrow ablation in the recipient. The beneficial treatment effect of this procedure is due to a combination of the initial eradication of malignant cells and subsequent graft-versus-malignancy effect mediated by non-self-immunologic effector cells. While the slower graft-versus-malignancy effect is considered the potentially curative component, it may be overwhelmed by existing disease in the absence of pretransplant conditioning. Intense conditioning regimens are limited to patients who are sufficiently medically fit to tolerate substantial adverse effects. These include opportunistic infections secondary to loss of endogenous bone marrow function and organ damage or failure caused by cytotoxic drugs. Subsequent to graft infusion in allo-HCT, immunosuppressant drugs are required to minimize graft rejection and graft-versus-host disease, which increases susceptibility to opportunistic infections.

The success of autologous HCT is predicated on the potential of cytotoxic chemotherapy, with or without radiotherapy, to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of the bone marrow with presumably normal hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. Therefore, autologous HCT is typically performed as consolidation therapy when the patient's disease is in complete remission. Patients who undergo autologous HCT are also susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVH disease.

#### **Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation**

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses of cytotoxic drugs or less intense regimens of radiotherapy than are used in traditional full-dose myeloablative conditioning

treatments. Although the definition of RIC is variable, with numerous versions employed, all regimens seek to balance the competing effects of relapse due to residual disease and non-relapse mortality. The goal of RIC is to reduce disease burden and to minimize associated treatment-related morbidity and non-relapse mortality in the period during which the beneficial graft-versus-malignancy effect of allogeneic transplantation develops. RIC regimens range from nearly total myeloablative to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism. In this review, the term reduced-intensity conditioning will refer to all conditioning regimens intended to be nonmyeloablative.

## Summary

A number of inherited and acquired conditions have the potential for severe and/or progressive disease. For some conditions, allogeneic hematopoietic cell transplantation (allo-HCT) has been used to alter the natural history of the disease or potentially offer a cure.

For individuals who have a hemoglobinopathy, bone marrow failure syndrome, primary immunodeficiency, inherited metabolic syndrome disease (specifically those other than Hunter, Sanfilippo, or Morquio syndromes), or a genetic disorder affecting skeletal tissue who receive allo-HCT, the evidence includes mostly case series, case reports, and registry data. Relevant outcomes are overall survival, disease-specific survival, symptoms, quality of life, and treatment-related morbidity. The evidence has shown that, for most of these disorders, there is a demonstrable improvement in overall survival and other disease-specific outcomes. Allo-HCT is likely to improve health outcomes in select patients with certain inherited and acquired diseases. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have an inherited metabolic syndrome disease (specifically those including Hunter, Sanfilippo, and Morquio syndromes) who receive allo-HCT, the evidence includes case reports. Relevant outcomes are overall survival, disease-specific survival, symptoms, quality of life, and treatment-related morbidity. Use of allo-HCT to treat patients with Hunter, Sanfilippo, or Morquio syndromes does not result in improvements in neurologic, neuropsychologic, and neurophysiologic function. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## Policy History

Date	Action
9/2023	Policy clarified to include prior authorization requests using Authorization Manager.
3/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference.
4/2020	Bone marrow harvesting codes were removed. Outpatient prior authorization is not required.
3/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
3/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2019	Outpatient prior authorization is required for all commercial products. Effective 1/1/2019.
2/2018	Annual policy review. New references added.
12/2017	Annual policy review. "Stem" removed from title and Policy. HSCT changed to HCT in policy text. Policy statement unchanged. 12/1/2017
3/2016	Annual policy review. New references added.
9/2015	Clarified coding information.
6/2014	Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.



12/2013	Annual policy review. New references added.
12/2012	Updated to add new CPT code 38243.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
7/2011	Reviewed - Medical Policy Group - Hematology and Oncology. No changes to policy statements.
9/2010	Reviewed - Medical Policy Group - Hematology and Oncology. No changes to policy statements.
6/1/2010	New policy, effective 6/1/2010, describing covered and non-covered indications.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. Bhatia M, Walters MC. Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. *Bone Marrow Transplant.* Jan 2008; 41(2): 109-17. PMID 18059330
2. Mehta P. Hematopoietic stem cell transplantation for inherited bone marrow failure syndromes. In: Mehta P, ed. *Pediatric Stem Cell Transplantation.* Sudbury, MA: Jones and Bartlett; 2004:281-316.
3. Gluckman E, Wagner JE. Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome. *Bone Marrow Transplant.* Jan 2008; 41(2): 127-32. PMID 18084332
4. Gennery AR, Cant AJ. Advances in hematopoietic stem cell transplantation for primary immunodeficiency. *Immunol Allergy Clin North Am.* May 2008; 28(2): 439-56, x-xi. PMID 18424341
5. Porta F, Forino C, De Martiis D, et al. Stem cell transplantation for primary immunodeficiencies. *Bone Marrow Transplant.* Jun 2008; 41 Suppl 2: S83-6. PMID 18545252
6. Prasad VK, Kurtzberg J. Emerging trends in transplantation of inherited metabolic diseases. *Bone Marrow Transplant.* Jan 2008; 41(2): 99-108. PMID 18176609
7. Askmyr MK, Fasth A, Richter J. Towards a better understanding and new therapeutics of osteopetrosis. *Br J Haematol.* Mar 2008; 140(6): 597-609. PMID 18241253
8. MacMillan ML, Walters MC, Gluckman E. Transplant outcomes in bone marrow failure syndromes and hemoglobinopathies. *Semin Hematol.* Jan 2010; 47(1): 37-45. PMID 20109610
9. Smiers FJ, Krishnamurti L, Lucarelli G. Hematopoietic stem cell transplantation for hemoglobinopathies: current practice and emerging trends. *Pediatr Clin North Am.* Feb 2010; 57(1): 181-205. PMID 20307718
10. Angelucci E, Matthes-Martin S, Baronciani D, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. *Haematologica.* May 2014; 99(5): 811-20. PMID 24790059
11. Mathews V, Srivastava A, Chandy M. Allogeneic stem cell transplantation for thalassemia major. *Hematol Oncol Clin North Am.* Dec 2014; 28(6): 1187-200. PMID 25459187
12. Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. *Blood.* Aug 08 2013; 122(6): 1072-8. PMID 23692854
13. Mehta P. Hematopoietic stem cell transplantation for hemoglobinopathies. In: Mehta P, ed. *Pediatric Stem Cell Transplantation.* Sudbury, MA: Jones and Bartlett; 2004:259-279.
14. Mahmoud HK, Elhaddad AM, Fahmy OA, et al. Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders. *J Adv Res.* May 2015; 6(3): 449-58. PMID 26257943
15. Bernardo ME, Piras E, Vacca A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. *Blood.* Jul 12 2012; 120(2): 473-6. PMID 22645178

16. Anurathapan U, Pakakasama S, Mekjaruskul P, et al. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. *Biol Blood Marrow Transplant.* Dec 2014; 20(12): 2066-71. PMID 25064743
17. Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. *Cochrane Database Syst Rev.* May 31 2013; (5): CD007001. PMID 23728664
18. Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. *Cochrane Database Syst Rev.* May 19 2016; (5): CD007001. PMID 27194464
19. Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. *Cochrane Database Syst Rev.* Jul 03 2020; 7: CD007001. PMID 32617981
20. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. *Blood.* Oct 01 2007; 110(7): 2749-56. PMID 17606762
21. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. *N Engl J Med.* Aug 08 1996; 335(6): 369-76. PMID 8663884
22. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. *Blood.* Mar 15 2000; 95(6): 1918-24. PMID 10706855
23. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. *JAMA.* Jul 02 2014; 312(1): 48-56. PMID 25058217
24. Mehta P, Locatelli F, Stary J, et al. Bone marrow transplantation for inherited bone marrow failure syndromes. *Pediatr Clin North Am.* Feb 2010; 57(1): 147-70. PMID 20307716
25. Miano M, Dufour C. The diagnosis and treatment of aplastic anemia: a review. *Int J Hematol.* Jun 2015; 101(6): 527-35. PMID 25837779
26. Bacigalupo A. Bone marrow transplantation for acquired severe aplastic anemia. *Hematol Oncol Clin North Am.* Dec 2014; 28(6): 1145-55. PMID 25459184
27. Yabe M, Morio T, Tabuchi K, et al. Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis. *Int J Hematol.* Jan 2021; 113(1): 134-144. PMID 32949371
28. Dufour C, Svahn J. Fanconi anaemia: new strategies. *Bone Marrow Transplant.* Jun 2008; 41 Suppl 2: S90-5. PMID 18545254
29. Zanis-Neto J, Flowers ME, Medeiros CR, et al. Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia. *Br J Haematol.* Jul 2005; 130(1): 99-106. PMID 15982351
30. Wagner JE, Eapen M, MacMillan ML, et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. *Blood.* Mar 01 2007; 109(5): 2256-62. PMID 17038525
31. Gadalla SM, Sales-Bonfim C, Carreras J, et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. *Biol Blood Marrow Transplant.* Aug 2013; 19(8): 1238-43. PMID 23751955
32. Cesaro S, Oneto R, Messina C, et al. Haematopoietic stem cell transplantation for Shwachman-Diamond disease: a study from the European Group for blood and marrow transplantation. *Br J Haematol.* Oct 2005; 131(2): 231-6. PMID 16197455
33. Myers K, Hebert K, Antin J, et al. Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome. *Biol Blood Marrow Transplant.* Aug 2020; 26(8): 1446-1451. PMID 32428734
34. Cesaro S, Pillon M, Sauer M, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT). *Bone Marrow Transplant.* Sep 2020; 55(9): 1796-1809. PMID 32203264
35. Roy V, Perez WS, Eapen M, et al. Bone marrow transplantation for diamond-blackfan anemia. *Biol Blood Marrow Transplant.* Aug 2005; 11(8): 600-8. PMID 16041310
36. ElGohary G, El Fakih R, de Latour R, et al. Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). *Bone Marrow Transplant.* Oct 2020; 55(10): 1906-1917. PMID 32346079

37. Kim H, Lee JH, Joo YD, et al. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. *Ann Hematol.* Sep 2012; 91(9): 1459-69. PMID 22526363
38. Dufour C, Pillon M, Socie G, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. *Br J Haematol.* May 2015; 169(4): 565-73. PMID 25683884
39. Smith AR, Gross TG, Baker KS. Transplant outcomes for primary immunodeficiency disease. *Semin Hematol.* Jan 2010; 47(1): 79-85. PMID 20109615
40. Szabolcs P, Cavazzana-Calvo M, Fischer A, et al. Bone marrow transplantation for primary immunodeficiency diseases. *Pediatr Clin North Am.* Feb 2010; 57(1): 207-37. PMID 20307719
41. Ahlin A, Fugelang J, de Boer M, et al. Chronic granulomatous disease-haematopoietic stem cell transplantation versus conventional treatment. *Acta Paediatr.* Nov 2013; 102(11): 1087-94. PMID 23937637
42. Gungor T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. *Lancet.* Feb 01 2014; 383(9915): 436-48. PMID 24161820
43. Chiesa R, Wang J, Blok HJ, et al. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. *Blood.* Sep 03 2020; 136(10): 1201-1211. PMID 32614953
44. Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. *Bone Marrow Transplant.* Aug 2008; 42 Suppl 1: S49-S52. PMID 18724301
45. Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. *Blood.* Oct 25 2012; 120(17): 3615-24; quiz 3626. PMID 22791287
46. Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. *Blood.* Mar 15 2001; 97(6): 1598-603. PMID 11238097
47. Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. *Blood.* Aug 11 2011; 118(6): 1675-84. PMID 21659547
48. Burroughs LM, Petrovic A, Brazauskas R, et al. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. *Blood.* Jun 04 2020; 135(23): 2094-2105. PMID 32268350
49. Marsh RA, Blesing JJ, Chandrakasan S, et al. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1. *Biol Blood Marrow Transplant.* Oct 2014; 20(10): 1641-5. PMID 24923536
50. Mehta P. Metabolic diseases. In: Mehta P, ed. *Pediatric Stem Cell Transplantation.* Sudbury, MA: Jones and Bartlett; 2004:233-258.
51. Guffon N, Bertrand Y, Forest I, et al. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. *J Pediatr.* May 2009; 154(5): 733-7. PMID 19167723
52. Vellodi A, Young E, New M, et al. Bone marrow transplantation for Sanfilippo disease type B. *J Inherit Metab Dis.* 1992; 15(6): 911-8. PMID 1293388
53. Bordigoni P, Vidailbet M, Lena M, et al. Bone marrow transplantation for Sanfilippo syndrome. In: Hobbs JR, ed. *Correction of Certain Genetic Diseases by Transplantation.* London: Cogent; 1989:114-119.
54. Boelens JJ, Prasad VK, Tolar J, et al. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. *Pediatr Clin North Am.* Feb 2010; 57(1): 123-45. PMID 20307715
55. Prasad VK, Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. *Semin Hematol.* Jan 2010; 47(1): 59-69. PMID 20109613

56. Rovelli AM. The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: an update. *Bone Marrow Transplant*. Jun 2008; 41 Suppl 2: S87-9. PMID 18545253
57. Aldenhoven M, Wynn RF, Orchard PJ, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. *Blood*. Mar 26 2015; 125(13): 2164-72. PMID 25624320
58. Boelens JJ, Wynn RF, O'Meara A, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. *Bone Marrow Transplant*. Aug 2007; 40(3): 225-33. PMID 17529997
59. Hansen MD, Filipovich AH, Davies SM, et al. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. *Bone Marrow Transplant*. Feb 2008; 41(4): 349-53. PMID 18026148
60. Mynarek M, Tolar J, Albert MH, et al. Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. *Bone Marrow Transplant*. Mar 2012; 47(3): 352-9. PMID 21552297
61. Miller WP, Rothman SM, Nascene D, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. *Blood*. Aug 18 2011; 118(7): 1971-8. PMID 21586746
62. Steward CG. Hematopoietic stem cell transplantation for osteopetrosis. *Pediatr Clin North Am*. Feb 2010; 57(1): 171-80. PMID 20307717
63. Driessen GJ, Gerritsen EJ, Fischer A, et al. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMT report. *Bone Marrow Transplant*. Oct 2003; 32(7): 657-63. PMID 13130312
64. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. Nov 2015; 21(11): 1863-1869. PMID 26256941
65. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. *Br J Haematol*. Jan 2016; 172(2): 187-207. PMID 26568159
66. Barone A, Lucarelli A, Onofrillo D, et al. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). *Blood Cells Mol Dis*. Jun 2015; 55(1): 40-7. PMID 25976466